IL15 and non-small cell lung carcinoma: In a phase I clinical trial evaluating the safety of the intravenous administration of allogeneic NK cells combined with chemotherapy, researchers treated non-small-cell lung cancer (NSCLC) patients with allogeneic NK cells expanded ex vivo using IL-15 and hydrocortisone.